1. Home
  2. ALT vs TCMD Comparison

ALT vs TCMD Comparison

Compare ALT & TCMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • TCMD
  • Stock Information
  • Founded
  • ALT 1997
  • TCMD 1995
  • Country
  • ALT United States
  • TCMD United States
  • Employees
  • ALT N/A
  • TCMD N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • TCMD Medical/Dental Instruments
  • Sector
  • ALT Health Care
  • TCMD Health Care
  • Exchange
  • ALT Nasdaq
  • TCMD Nasdaq
  • Market Cap
  • ALT 292.8M
  • TCMD 235.5M
  • IPO Year
  • ALT N/A
  • TCMD 2016
  • Fundamental
  • Price
  • ALT $3.61
  • TCMD $9.89
  • Analyst Decision
  • ALT Strong Buy
  • TCMD Hold
  • Analyst Count
  • ALT 6
  • TCMD 3
  • Target Price
  • ALT $18.20
  • TCMD $16.00
  • AVG Volume (30 Days)
  • ALT 3.5M
  • TCMD 182.5K
  • Earning Date
  • ALT 08-15-2025
  • TCMD 08-04-2025
  • Dividend Yield
  • ALT N/A
  • TCMD N/A
  • EPS Growth
  • ALT N/A
  • TCMD N/A
  • EPS
  • ALT N/A
  • TCMD 0.66
  • Revenue
  • ALT $20,000.00
  • TCMD $293,164,000.00
  • Revenue This Year
  • ALT N/A
  • TCMD $7.96
  • Revenue Next Year
  • ALT $346,228.97
  • TCMD $8.53
  • P/E Ratio
  • ALT N/A
  • TCMD $14.98
  • Revenue Growth
  • ALT N/A
  • TCMD 5.96
  • 52 Week Low
  • ALT $2.90
  • TCMD $8.61
  • 52 Week High
  • ALT $11.16
  • TCMD $21.10
  • Technical
  • Relative Strength Index (RSI)
  • ALT 34.75
  • TCMD 46.33
  • Support Level
  • ALT $3.58
  • TCMD $10.09
  • Resistance Level
  • ALT $4.39
  • TCMD $10.76
  • Average True Range (ATR)
  • ALT 0.19
  • TCMD 0.39
  • MACD
  • ALT -0.00
  • TCMD -0.02
  • Stochastic Oscillator
  • ALT 4.65
  • TCMD 35.45

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About TCMD Tactile Systems Technology Inc.

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

Share on Social Networks: